Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 980,100 shares, an increase of 709.3% from the December 15th total of 121,100 shares. Based on an average trading volume of 335,500 shares, the short-interest ratio is currently 2.9 days.
Evaxion Biotech A/S Trading Down 11.1 %
EVAX stock traded down $0.47 during midday trading on Tuesday, hitting $3.78. The stock had a trading volume of 135,045 shares, compared to its average volume of 53,329. The firm has a market cap of $22.17 million, a PE ratio of -13.03 and a beta of -0.23. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 12-month low of $3.32 and a 12-month high of $68.05. The company’s 50-day moving average price is $6.75 and its 200 day moving average price is $11.93.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last released its earnings results on Thursday, October 31st. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.40. The firm had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. On average, equities research analysts predict that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Research Report on Evaxion Biotech A/S
Institutional Trading of Evaxion Biotech A/S
A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Invst LLC purchased a new position in shares of Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned 1.00% of Evaxion Biotech A/S at the end of the most recent quarter. Institutional investors own 11.04% of the company’s stock.
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.
Featured Articles
- Five stocks we like better than Evaxion Biotech A/S
- What is the Dogs of the Dow Strategy? Overview and Examples
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- Election Stocks: How Elections Affect the Stock Market
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Invest in Insurance Companies: A GuideĀ
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.